- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innovent Biologics Inc (1801)
Innovent Biologics Inc stock price live, this page displays HK 1801 stock exchange data. View the 1801 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Innovent Biologics Inc real time stock price chart below.
What Is the Innovent Biologics Inc Stock Price Today?
The Innovent Biologics Inc stock price today is 97.75.
What Is the Stock Symbol for Innovent Biologics Inc?
The stock symbol for Innovent Biologics Inc is ""1801.""
What Stock Exchange Does Innovent Biologics Inc Trade On?
Innovent Biologics Inc is listed and trades on the Hong Kong stock exchange.
Is Innovent Biologics Inc a Good Stock to Buy?
Determining whether Innovent Biologics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1801 quote. (ISIN: KYG4818G1010)
What Is the Innovent Biologics Inc Stock Price Today?
The Innovent Biologics Inc stock price today is 97.75.
What Is the Stock Symbol for Innovent Biologics Inc?
The stock symbol for Innovent Biologics Inc is ""1801.""
What Stock Exchange Does Innovent Biologics Inc Trade On?
Innovent Biologics Inc is listed and trades on the Hong Kong stock exchange.
Is Innovent Biologics Inc a Good Stock to Buy?
Determining whether Innovent Biologics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1801 quote. (ISIN: KYG4818G1010)
Hong Kong
Currency in HKD
97.75
-4.15(-4.07%)
Closed·
Fair Value
An estimate of a Innovent Biologics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
96.00
102.90
52 wk Range
28.65
106.00
1801 Scorecard
Full Analysis
Net income is expected to grow this year
1801 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Innovent Biologics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
96.00102.90
52 wk Range
28.65106.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
1801 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Innovent Biologics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
86.43
Downside
-11.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Innovent Biologics Inc Company Profile
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
Compare 1801 to Peers and Sector
Metrics to compare | 1801 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1801PeersSector | |
|---|---|---|---|---|
P/E Ratio | −1,627.8x | −7.4x | −0.6x | |
PEG Ratio | −17.91 | 0.44 | 0.00 | |
Price/Book | 11.7x | 7.2x | 2.6x | |
Price / LTM Sales | 16.3x | 15.5x | 3.3x | |
Upside (Analyst Target) | −8.3% | −17.4% | 39.1% | |
Fair Value Upside | Unlock | −21.1% | 4.5% | Unlock |
Analyst Ratings
28 Buy
2 Hold
1 Sell
Ratings:
31 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 86.43
(-11.58% Downside)
Earnings
Latest Release
Apr 28, 2025
EPS / Forecast
0.18 / -0.55
Revenue / Forecast
5.47B / --
People Also Watch
FAQ
What Stock Exchange Does Innovent Biologics Trade On?
Innovent Biologics is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for Innovent Biologics?
The stock symbol for Innovent Biologics is "1801."
What Is the Innovent Biologics Market Cap?
As of today, Innovent Biologics market cap is 167.68B.
What Is Innovent Biologics's Earnings Per Share (TTM)?
The Innovent Biologics EPS (TTM) is -0.06.
From a Technical Analysis Perspective, Is 1801 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Innovent Biologics Stock Split?
Innovent Biologics has split 0 times.
How Many Employees Does Innovent Biologics Have?
Innovent Biologics has 5659 employees.
What is the current trading status of Innovent Biologics (1801)?
As of 19 Aug 2025, Innovent Biologics (1801) is trading at a price of 97.75, with a previous close of 101.90. The stock has fluctuated within a day range of 96.00 to 102.90, while its 52-week range spans from 28.65 to 106.00.
What Is Innovent Biologics (1801) Price Target According to Analysts?
The average 12-month price target for Innovent Biologics is HKD86.43361271, with a high estimate of HKD119.87591161 and a low estimate of HKD40.66071623. 28 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an -11.58% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.